A5006391058- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Head and Neck Cancer Studies
- Cancer Diagnosis and Treatment
- Breast Lesions and Carcinomas
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Cancer survivorship and care
- Thyroid Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Global Cancer Incidence and Screening
- Oral health in cancer treatment
- Estrogen and related hormone effects
- Regional Development and Management Studies
- Lung Cancer Treatments and Mutations
- Immune cells in cancer
- Skin and Cellular Biology Research
- Cancer-related Molecular Pathways
- Ovarian cancer diagnosis and treatment
- Advances in Oncology and Radiotherapy
University of Basel
2024-2025
Breast Center
2025
University Hospital of Basel
2023-2025
Institute of Oncology Ljubljana
2015-2024
University of Ljubljana
2000-2024
Cedars-Sinai Medical Center
1991
Abstract The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety cancer types. In breast cancer, preclinical studies showed that inhibitors the Na + /K ATPase suppress CTC block metastasis. Here we conducted prospective, open-label, proof-of-concept study women metastatic where primary objective was to determine whether treatment inhibitor digoxin could reduce mean cluster size. An analysis nine patients treated daily...
Proliferation determined by Ki-67 immunohistochemistry has been proposed as a useful prognostic and predictive marker in breast cancer. However, the clinical validity of is questionable. In this study, was retrospectively evaluated three pathologists using two methods: visual assessment entire slide quantitative tumour margin 411 early-stage cancer patients with median follow-up 26.8 years. We found excellent agreement between for both methods. The risk recurrence time-dependent, high...
Patients with cancer are at high risk for serious illness and death from COVID-19. The pandemic has altered the routine oncology patients. Their lives depend on their ability to receive medical care, but every visit a health-care facility exposes them of contracting virus; therefore, concerns about getting infected might interfere continuity care. Does treatment outweigh infection? psychological pressure uncertainty patients is particularly high. In this difficult phase, these need guidance...
A high proportion of metastatic melanoma patients do not respond to immune checkpoint inhibitors (ICI), and until now, no validated biomarkers for response survival have been known.We performed a retrospective analysis outcomes in with treated first-line ICI at the Institute Oncology Ljubljana from January 2018 December 2020. The immune-related adverse events (irAEs) serum immune-inflammation parameters (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (LR), systemic index (SII)...
Background Immune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent metastatic head neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit trials is variable heterogeneous. Our study aims at exploring comparing predictive role gene-expression signatures with classical biomarkers for immunotherapy-treated R/M HNSCC patients a multicentric phase IIIb trial. Methods Clinical data were prospectively collected Nivactor tiral...
Providing patients with cancer who are undergoing systemic therapy useful information about symptom management is essential to prevent unnecessary deterioration of quality life.The aim was evaluate whether use an app for associated any change in patient life or health resources.Outpatients early stage breast receiving were recruited at the Institute Oncology Ljubljana, Slovenia. Patients received between December 2017 and March 2018 (control group) April September (intervention eligible. All...
Circulating tumor cell count is an independent prognostic factor in early breast cancer. CTCs can be found the blood of 20% patients prior to neoadjuvant therapy. We aimed assess suitability magnetic-activated separation (MACS) technology for isolation and cytological characterization CTCs. In preclinical part study, lines were spiked into buffy coat samples derived from healthy donors, isolated using MACS. Breast cancer cells with preserved morphology successfully isolated. clinical part,...
Neoadjuvant systemic treatment (NST) is the standard for HER2+, triple-negative (TN), and highly proliferative luminal HER2− early breast cancer. Pathologic complete response (pCR) after NST associated with improved outcomes. We evaluated predictive factors axillary-pCR (AXpCR) its impact on extent of axillary node surgery. This retrospective study included 92 patients (median age 50.4 years) an initially node-positive disease. Patients were treated molecular subtype-specific (4.3% A-like,...
As compared to tamoxifen aromatase inhibitors (AIs) may increase the risk of heart disease. Here we explored association between use AIs and coronary artery disease (CAD) in a population-based observational study. In small heterogeneous population 74 women with early breast cancer who received adjuvant hormonal therapy subsequently underwent cardiac angiography, significantly increased hazard for CAD (HR 3.23, 95% confidence intervals [CI] 1.26–8.25, p = .01) tamoxifen. Our results suggest that CAD.
High-grade serous carcinoma (HGSC) is often associated with ascites at presentation. Our objective was to quantify immune cells (ICs) in prior any treatment given and evaluate their impact on progression-free survival (PFS) overall (OS).Forty-seven patients primary HGSC were included. Flow-cytometric analysis performed detect percentages of CD3+ T (CD4+, CD8+, Tregs, NKT cells), B cells, NK (CD56brightCD16- CD56dimCD16+ subsets), macrophages dendritic (DCs). Furthermore, CD103 expression...
Liquid biopsy is becoming an important source of new biomarkers during the treatment metastatic cancer patients. Using size-based microfluid technology, we isolated circulating tumor cells (CTCs) from breast patients to evaluate their presence and cluster formation, as well megakaryocytes immune-inflammatory blood cells, correlate with clinicopathological data overall survival (OS). In total, 59 (median age 60.4 years) were included in study: 62.7% luminal A/B-like, 20.3% HER2-positive, 17%...
The purpose of this study was to assess the efficacy and toxicity docetaxel, cisplatin/5-fluorouracil (TPF) induction chemotherapy concomitant immunochemoradiotherapy with cetuximab cisplatin in unresectable head neck carcinoma.Treatment consisted TPF (docetaxel 75 mg/m(2) day 2; cisplatin, 5-fluorouracil 750 days 1-4; 4 cycles), followed by radiotherapy (RT) weekly cetuximab, (250 mg/m(2), after a loading dose 400 mg/m(2)) (30 mg/m(2)).Twenty-five 30 patients completed cycles chemotherapy....
Abstract Background Circulating tumor cells (CTCs) have become an important biomarker in breast cancer. Different isolation tech-niques based on their biological or physical features were established. Currently, the most widely used methods for visualization after separation are immunofluorescent staining, which does not provide information morphology. Materials and The aim of this study was to evaluate how two different techniques affect cell morphology analyse with routine cytopathological...
Neuroendocrine carcinomas (NECs) of the head and neck are rare experience scanty. The Cancer Registry Slovenia database was used to identify cases laryngeal pharyngeal NECs diagnosed between 1995-2020. Biopsies were analyzed for expression standard neuroendocrine markers (synaptophysin, chromogranin, CD56), INSM1, Ki-67, p16, PD-L1 (using combined positive score, CPS). In situ hybridization human papillomavirus (HPV) Epstein-Barr virus (EBV) performed. Twenty patients (larynx, 12; pharynx,...
Low response rates in immune check-point blockade (ICB)-treated head and neck squamous cell carcinoma (HNSCC) drive a critical need for robust, clinically validated predictive biomarkers. Our group previously showed that stress keratin 17 (CK17) suppresses macrophage-mediated CXCL9/CXCL10 chemokine signaling involved attracting activated CD8+ T cells into tumors, correlating with decreased rate to pembrolizumab-based therapy pilot cohort of ICB-treated HNSCC (n = 26). Here, we performed an...
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in range 40-50% and reduces risk dying from HER2 by one third. Adjuvant treatment became available Slovenia 2005 aim this study to explore, if exceptional results reported clinical trials are achieved also daily practice.An analysis tumour patient characteristics, type outcome (relapse overall...